Methotrexate vs Pembrolizumab
Methotrexate vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Methotrexate and Pembrolizumab.
Mechanism of Action
Methotrexate: Dihydrofolate reductase inhibitor.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Methotrexate — 3-10 hours; Pembrolizumab — 26 days.
Chemical Properties
Molecular Formula: Methotrexate — C20H22N8O5.
Molecular Weight: Methotrexate — 454.4400 g/mol.
Type: Methotrexate — Small molecule; Pembrolizumab — Antibody.